Regulus Therapeutics (RGLS) Reports In-Line Q4 EPS

Regulus Therapeutics (NASDAQ: RGLS) reported Q4 EPS of ($0.07), in-line with the analyst estimate of ($0.07).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• Dollar Tree upgraded on earnings upside potential despite ongoing traffic woes
• Helen of Troy (HELE) Tops Q1 EPS by 22c, Beats on Revenue; Offers FY Guidance
• PriceSmart (PSMT) Misses Q3 EPS by 4c, Beats on Revenue